Preetesh Jain
Assistant Professor, Department of Lymphoma and Myeloma
MD Anderson Cancer Center · Houston, United States
Rising MCL expert at MD Anderson focused on novel combinations and outcomes in high-risk MCL, particularly TP53-mutated disease. Published extensively on BTK inhibitor resistance and bispecific antibodies.
Correction: Exploiting PRMT5 as a target for combination therapy in mantle cell lymphoma characterized by frequent ATM and TP53 mutations.
Blood cancer journal · Apr 8, 2026
Mitochondrial ACSS1 Links Acetate Metabolism to Pyrimidine Biosynthesis in Nutrient-Stressed B-Cell Lymphomas.
Cancer letters · Apr 7, 2026
Benefit of rituximab maintenance after first-line bendamustine-rituximab in patients with mantle cell lymphoma.
Blood advances · Feb 24, 2026
Integrative profiling strategies to guide personalized therapy in mantle cell lymphoma: a pilot study.
NPJ precision oncology · Nov 21, 2025
TCA cycle mode switch determines the fate of pirtobrutinib-tolerant persister cells in mantle cell lymphoma.
Blood · Nov 20, 2025
Treatment and outcomes of progression of disease post-CAR T-cell therapy in mantle cell lymphoma: a multicenter analysis.
Blood advances · Nov 11, 2025
Optical genome mapping reveals diverse mechanisms of cyclin activation in mantle cell lymphomas lacking IGH::CCND1.
Human pathology · May 1, 2025
Phase 2 trial of ibrutinib in previously untreated high-risk smoldering mantle cell lymphoma.
Leukemia & lymphoma · May 1, 2025
Targeting the DNA damage response through TBL1X in mantle cell lymphoma.
Blood advances · Apr 22, 2025
High-risk MCL: recognition and treatment.
Blood · Feb 13, 2025
Chimeric Antigen Receptor T-Cell-Associated Cholangiopathy: First Reported Case of a Complication of Chimeric Antigen Receptor T-Cell Therapy.
ACG case reports journal · Jan 1, 2025
Characteristics, treatment, and outcomes of mantle cell lymphoma with cutaneous involvement: a decade-long study at MD Anderson cancer center.
Leukemia & lymphoma · Nov 1, 2024
Author Correction: Longitudinal single-cell profiling reveals molecular heterogeneity and tumor-immune evolution in refractory mantle cell lymphoma.
Nature communications · Oct 7, 2024
Targeting CERS6-AS1/FGFR1 axis as synthetic vulnerability to constrain stromal cells supported proliferation in Mantle cell lymphoma.
Leukemia · Oct 1, 2024
Correction: Targeting CERS6-AS1/FGFR1 axis as synthetic vulnerability to constrain stromal cells supported proliferation in Mantle cell lymphoma.
Leukemia · Sep 1, 2024
Biclonal mantle cell lymphoma.
Blood · May 23, 2024
Efficacy and safety of brexucabtagene autoleucel CAR T-cell therapy with BTK inhibitors in the treatment of relapsed mantle cell lymphoma with central nervous system involvement.
Leukemia & lymphoma · May 1, 2024
Applying the EHA/EBMT grading for ICAHT after CAR-T: comparative incidence and association with infections and mortality.
Blood advances · Apr 23, 2024
TP53 mutation is frequent in mantle cell lymphoma with EZH2 expression and have dismal outcome when both are present.
Human pathology · Apr 1, 2024
SOX11+ Large B-Cell Neoplasms: Cyclin D1-Negative Blastoid/Pleomorphic Mantle Cell Lymphoma or Large B-Cell Lymphoma?
Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc · Feb 1, 2024
Optical genomic mapping is a helpful tool for detecting CCND1 rearrangements in CD5-negative small B-cell lymphoma: Two cases of leukemic non-nodal mantle cell lymphoma.
Human pathology · Feb 1, 2024
Final results and overall survival data from a phase II study of acalabrutinib monotherapy in patients with relapsed/refractory mantle cell lymphoma, including those with poor prognostic factors.
Haematologica · Jan 1, 2024